Aptatek BioSciences Attracts Bridge Financing

Aptatek BioSciences Inc. has received bridge financing from Canterbury Scientific Ltd., a current strategic investor. The latest funding tranche follows the successful advancement of Aptatek’s PheCheck platform, a U.S. Food and Drug Administration breakthrough diagnostic device designed for at-home monitoring of phenylalanine levels in patients with phenylketonuria (PKU).

“This further funding from Canterbury Scientific strengthens our ability to bring our monitoring solution to PKU patients,” Aptatek CEO Dr. Michael Boyce-Jacino said. “We deeply value Canterbury’s continued confidence and strategic partnership as we move closer to commercialization.”

The new financing supports Aptatek’s ongoing clinical development and accelerates its path toward commercializing its DNA aptamer-based home monitor for PKU, a genetic metabolic disorder that requires diligent phenylalanine level monitoring to prevent serious health complications. As with diabetes management, maintaining optimal phenylalanine levels through diet and medication is essential for patient health and quality of life.

“Aptatek is at the forefront of revolutionizing home health management. We are excited to support the commercialization of their patient-centric approach to chronic disease monitoring, offering patients greater control over their health outcomes and daily lives,” Canterbury Scientific CEO Clive Seymour added.

Founded as a spin-out from Columbia University, Aptatek BioSciences Inc. leverages advanced aptamer technology to create simple, reliable, quantitative, point-of-care diagnostics that empower patients with chronic conditions to manage their health effectively from home.

Canterbury Scientific is a global OEM supplier of IVD controls.